kda received following announcement yesterday nord national organization rare disorders member nord supported proposal passage another important step living rare disorder key provisions bill outlined including accelerated approval process well providing incentives researchers provide focus rare disease therapies another important provision allow evaluation patient tolerance risks certain therapies including greater patient feedback praises senate addressing needs rare disease patients may washington dc national organization rare disorders nord applauds legislation passed today senate food drug administration safety innovation fdasia says contains comprehensive improvements public policy rare disease therapies since landmark orphan drug nord working hard past two years ensure interests rare disease patient community well represented important legislation said nord president ceo peter l saltonstall thrilled nation leaders congress working together making substantive policy improvements bring new therapies patients desperately need process began two years ago added focus obtaining commitment fda incorporate exceptional nature rare diseases review promising new therapies medical devices able achieve since members advocacy partners rare disease community nothing short astonishing sincerest thanks go helped make day possible bill contains numerous provisions enhance regulatory process fda incentivize investment innovators rare disease therapies expand scientific armamentarium needed bring cutting edge therapies patients quickly possible specific commitments fda include expanding rare disease program center drugs extension program center biologics new initiative qualify categorize biomarkers use clinical trial design including accelerated approval similar mechanisms new initiative evaluate patient tolerance risk proposed therapies incorporate patient input review process legislative provisions bill include codification modernization accelerated approval process improvements policies governing conflicts interest allow expert participation fda advisory committees creation new category breakthrough therapies encourage early public private collaboration aid clinical trial design review expanded access experts rare diseases beyond review process expansion devices intended use small patient populations including possibility profit devices used adult populations house representatives working companion legislation hr food drug administration reform already unanimously approved committee energy commerce similar bipartisan fashion adoption measure expected house resumes session beginning june house senate bills culmination process conducted every five years reauthorize prescription drug user fee pdufa related legislation provides critical funding allow fda review potential new therapies timely manner voice rare disease patients families since nord served primary representative rare disease patient community past two years needs prioritized legislation voted upon house senate drafted